.-Two myosin isoforms are expressed in myocardium, ␣␣-homodimers (V 1) and ␤␤-homodimers (V3). V1 exhibits higher velocities and myofibrillar ATPase activities compared with V 3. We also observed this for cardiac myosin from normal (V 1) and propylthiouracil-treated (V3) mice. Actin velocity in a motility assay (V actin) over V1 myosin was twice that of V 3 as was the myofibrillar ATPase. Myosin's average force (F avg) was similar for V1 and V3. Comparing Vactin and F avg across species for both V1 and V3, our laboratory showed previously (VanBuren P, Harris DE, Alpert NR, and Warshaw DM. Circ Res 77: 439-444, 1995) that mouse V 1 has greater V actin and Favg compared with rabbit V1. Mouse V3 Vactin was twice that of rabbit Vactin. To understand myosin's molecular structure and function, we compared ␣-and ␤-cardiac myosin sequences from rodents and rabbits. The rabbit ␣-and ␤-cardiac myosin differed by eight and four amino acids, respectively, compared with rodents. These residues are localized to both the motor domain and the rod. These differences in sequence and mechanical performance may be an evolutionary attempt to match a myosin's mechanical behavior to the heart's power requirements. contractile proteins; heart; motility assay; molecular motor THE POWER OUTPUT OF THE HEART is a key measure of ventricular performance, with power output being the rate at which the myocardium can perform work. At the cellular level, power output is a mechanical expression of the myocyte's force-velocity relationship (i.e., power ϭ force ϫ velocity), with the myocyte's ability to generate force and motion largely determined by the mechanoenzyme myosin. The myosin molecular motor interacts with actin to convert the energy from ATP hydrolysis into mechanical work.
THE POWER OUTPUT OF THE HEART is a key measure of ventricular performance, with power output being the rate at which the myocardium can perform work. At the cellular level, power output is a mechanical expression of the myocyte's force-velocity relationship (i.e., power ϭ force ϫ velocity), with the myocyte's ability to generate force and motion largely determined by the mechanoenzyme myosin. The myosin molecular motor interacts with actin to convert the energy from ATP hydrolysis into mechanical work.
Cardiac myosin is a dimeric protein, with each monomeric entity consisting of a myosin heavy chain (with hydrolytic and motor function) and two noncovalently bound light chains (53) . Two myosin heavy chain isoforms (␣ and ␤) exist in heart muscle, with the ␣␣-and ␤␤-homodimers referred to as V 1 and V 3 myosin, respectively (13) . The relative proportion of V 1 and V 3 expression depends on species, age, hormonal balance, and cardiovascular stress (8, 10, 17, 18, 22, 24) . Specifically, small mammals such as adult rodents (mouse and rat) predominantly express the V 1 isoform in the ventricle, whereas larger mammals (e.g., rabbits and humans) predominantly express the V 3 isoform. This species-dependent difference in isoform expression may be an etiologic attempt to match the mechanical performance of the V 1 and V 3 isoforms to the power requirements of the heart in these various species.
The mechanical properties of cardiac tissue are well correlated to the level of V 1 and V 3 expression (see Table 1 ). For example, heart muscles consisting primarily of the V 1 isoform have both higher maximum velocities of shortening (5, 19) and calcium-stimulated myofibrillar and actomyosin ATPase activities (31, 32, 46) than those containing primarily the V 3 isoform. In contrast, rabbit cardiac muscle expressing the V 3 isoform generates greater force-time integrals (12) , suggesting that V 3 myosin has greater force-generating potential. These isoform-dependent mechanical properties reflect the molecular mechanics of the individual myosin molecular motors. In an in vitro motility assay, which serves as a simplified model system for muscle contraction (49) , individual actin filaments in contact with V 1 myosin move two to three times faster than those in contact with the V 3 isoform, regardless of the mammalian species (7, 36, 46) . In addition, our laboratory showed (11, 46) that V 3 myosin from rabbit hearts generates twice the average force of V 1 myosin in the motility assay. However, Sugiura and coworkers reported (40, 41 ) that although rat V 1 moves actin twice as fast as V 3 , there is no difference in their average force generation. This apparent discrepancy (Table 1 ) may be, as suggested above, the result of evolutionary pressure to match cardiac and molecular motor function across species. Therefore, apparent differences in force generation between rodents and larger mammals may be a natural adaptation. To address this question, we studied the molecular mechanics, i.e., the average force (F avg ) and actin filament sliding velocity (V actin ) for mouse V 1 and V 3 myosin.
The results suggest that in the mouse, the dependence of V actin and F avg on cardiac myosin isoform is similar to that previously observed in the rat (40, 41) . We then took advantage of this inherent difference between rodent and rabbit cardiac myosins to begin probing how slight differences in amino acid sequence between these remarkably conserved myosin species relate to the functional performance of the molecular motor. In addition, the specific amino acid differences and their location pinpoint structural domains that are critical to myosin's mechanics and kinetics.
MATERIALS AND METHODS
Animal models and myosin preparation. Mice (FVB/N, 7-12 wk old, both sexes) were randomly separated into two groups. The nontreated mice had food and water ad libidum, whereas the treated animals had an iodine-deficient diet supplemented with 0.15% propylthiouracil (PTU) in drinking water for 8 wk before the experiment. The mice were treated with heparin (500 IU/kg ip) and then euthanized with CO 2. After thoracotomy, the heart was removed, placed in relaxing solution at 4°C [in mM: 5.37 ATP, 30 phosphocreatine, 5 EGTA, 20 N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid (BES), 7.33 MgCl 2, 0.12 CaCl2, 10 DTT, and 32 potassium methanesulfonate, with 10 g/ml leupeptin and 240 U/ml creatine phosphokinase, pCa 8.0, pH 7.0, ionic strength 175 mM]. Myosin used for isoform identification and motility assay was prepared as previously described (25, 44) . The relative composition of the cardiac ventricular myosin isoforms (3, 35) and the myofibrillar ATPase activity were determined by methods described previously (20, 32, 37) .
In vitro motility assay. Standard methods were used to carry out the in vitro motility assay with the important precaution of removing all nonfunctional myosin (27, 50) . Actin, prepared as previously described (28) was fluorescently labeled by overnight incubation with tetramethylrhodamine isothiocyanate-phalloidin (50) . Assays were carried out at 30°C by sequentially adding, briefly incubating, and removing the following proteins and solutions to and from a 30-l experimental chamber (for details see Ref. 27): 1) 100 g/ml myosin; 2) bovine serum albumin; 3) 1 M unlabeled actin in actin buffer (in mM: 25 KCl, 25 imidazole, 1 EGTA, 4 MgCl 2, 10 DTT with oxygen scavengers, pH 7.4); 4) actin buffer with 1 mM MgATP; 5) six 30-l washes with actin buffer; 6) 10 nM labeled actin; 7) 1 mM MgATP in actin buffer with 0.375% methylcellulose. Steps 3 and 4 and a comparable step in the initial myosin isolation procedure were presumed to remove denatured, rigorlike, nonfunctional myosin that might act as a load to the free movement of actin filaments in the motility assay (27) . When the myosin mixture assay was performed (see Relative average force determination) to compare the relative force-generating capacity of a fast and a slow myosin species, the two myosins were mixed in various proportions to a total concentration of 100 g/ml and then added to the experimental chamber in step 1 above. Actin filament movements were visualized and recorded as previously described (50) and digitally analyzed to determine V actin for the myosin isoforms (54) .
Relative average force determination. The relative Favg was determined with a myosin mixture assay in which fast and slow myosins were mixed and adhered to the motility surface (11, 50) . An estimate of the relative F avg for the two myosins can be obtained by fitting the relationship between Vactin and the percentage of fast and slow myosin on the motility surface to a model that assumes that myosins with different intrinsic speeds and forces interact with each other through the actin filament, resulting in the observed velocity of actin filament movement for a given mixture (11) . The estimate of F avg determined through this simple assay agrees well with a more direct but extremely difficult microneedle assay (11, 46, 47) . In this study, the V 1 and V3 myosins were mixed with each other or separately with an independent slower myosin, i.e., chicken gizzard smooth muscle myosin. A linear relationship of V actin versus the percentage of slow myosin implies that the fast and slow myosins have similar Favg. If the relationship is concave up, the Favg of the fast myosin is greater than that of the slow myosin. Conversely, if the relationship is concave down, the slow myosin has a greater F avg than the fast myosin. The estimate of the relative Favg for the V1 and V3 cardiac isoforms was obtained by fitting the data to the mechanical interactions model (11) with Sigmaplot 2000 (SPSS, Chicago, IL).
Primary sequence comparisons. Alignment and comparison of all available complete mammalian V 1 (i.e., ␣-cardiac) amino acid sequences was performed with the ALIGN and CLUSTALW algorithms on the San Diego Supercomputer Center Biology Workbench Website (http://workbench. sdsc.edu/). The V 1 myosin sequences were from golden hamster (SWISSPROT:MYH6_MESAU; 1,939 amino acids), mouse (SWISSPROT:MYH6_MOUSE; 1,938 amino acids), rat (SWISSPROT:MYH6_RAT; 1,938 amino acids), New Zealand White rabbit (J. Gulick and J. Robbins, unpublished data; 1,939 amino acids), and human (SWISSPROT: MYH6_HUMAN; 1,939 amino acids). With ALIGN, any two sequences can be aligned and the residues at a given sequence location characterized as being identical, a conservative replacement, or a nonconserved substitution. All five ␣-cardiac myosin sequences (i.e., hamster, mouse, rat, rabbit, and human) were then aligned simultaneously with CLUST-ALW. With this program, residues were characterized as identical, showing conservation of strong groups, showing conservation of weak groups, or showing no consensus. A similar comparison protocol was performed for the available complete mammalian V 3 (i.e., ␤-cardiac) myosin sequences from golden hamster (SWISSPROT:MYH7_MESAU; 1,934 amino acids), mouse (TrEMBL:Q91Z83; 1,935 amino acids), rat (SWISSPROT:MYH7_RAT; 1,935 amino acids), New Zealand White rabbit (J. Gulick and J. Robbins, unpublished data; 1,935 amino acids), pig (SWISSPROT:MYH7_PIG; 1,935 amino acids), and human (SWISSPROT: MYH7_HUMAN; 1,935 amino acids). All programs were used with default settings for all user-defined parameters.
RESULTS

Myofibrillar
ATPase and V actin for V 1 and V 3 mouse myosin. Myosin was isolated from normal and PTUtreated mice. The myosin expression in the ventricle of normal adult mice is 95-99% V 1 as estimated by gel electrophoresis (Fig. 1) . In contrast, the PTU-treated animals experienced a shift in expression to predominantly the V 3 isoform (80-95%; see Fig. 1 ). This shift resulted in an approximately twofold reduction in the 
Nos. in parentheses indicate references myofibrillar ATPase activity at all pCa levels without any affect on the pCa for half-maximal activity (i.e., pCa 6.0; see Fig. 2 , Table 2 ). The velocity of actin filament sliding as assessed in the in vitro motility assay was 5.5 Ϯ 0.2 and 2.6 Ϯ 0.4 m/s (P Ͻ 0.001) for the V 1 and V 3 myosin isoforms, respectively ( Table 2 ). The twofold-increased V actin for the V 1 compared with the V 3 myosin is similar to the ratio of the V 1 versus V 3 myofibrillar ATPase activities, suggesting that the myosin's hydrolytic activity is correlated with its velocity of actin movement (45) as originally proposed by Barany (2) for whole muscle. We initially mixed the V 1 and V 3 isoforms in varying proportions and determined the relationship for V actin as a function of the V 1 -V 3 percentage mixture on the motility surface. V actin was proportional to the V 1 -V 3 mixture (Fig. 3A) . Fitting these data to the mixture model resulted in a relatively linear fit (Fig. 3A) , with the model fit predicting a V 3 -to-V 1 F avg ratio of 1.2 Ϯ 0.1 (SE). This is in contrast to the two-to threefold difference we previously observed for rabbit myosin (11, 46) .
To further substantiate this finding, we performed mixture assays in which the V 1 and V 3 myosins were mixed independently with the slower gizzard smooth muscle myosin (Fig. 3 , B and C). We chose smooth muscle myosin because of its high F avg relative to all other muscle myosins (11, 47) . If in fact smooth muscle myosin generates greater F avg compared with the mouse cardiac isoforms, the mixture assay should result in relationships between V actin and the percentage of V 1 or V 3 in the presence of smooth muscle myosin having significant curvature, with the curvature being concave downward. This was the case for the V 1 versus smooth muscle myosin and V 3 versus smooth muscle myosin mixtures (see Fig. 3 , B and C). Fitting these mixture data to the model predicts that the smooth muscle myosin generates greater F avg than either mouse cardiac myosin isoform, with the fits to the model plotted as a solid curve in Fig. 3 , B and C. The fits gave a smooth muscle-to-V 3 F avg ratio of 2.7 Ϯ 0.4 and a smooth muscle-to-V 1 F avg ratio of 3.1 Ϯ 0.3. On the basis of these two independent mixtures, one can calculate the V 3 -to-V 1 F avg ratio to be 1.1 Ϯ 0.1. This estimate is in agreement with the estimate obtained from the direct V 1 -V 3 mixture experiment. Thus F avg values for V 1 and V 3 mouse cardiac myosin are similar, although the V actin values differ by twofold.
DISCUSSION
Marked differences exist in the hydrolytic and mechanical performance of the V 1 and V 3 cardiac myosin Equal amounts of ventricular protein (0.5 mg) from control (left) and PTU-treated (right) mice were loaded onto a 5% glycerol gel under denaturing conditions and electrophoresed to separate the V1 and V3 isoforms. After electrophoresis, the gels were stained with silver and band intensities were determined with NIH Image (i.e., 100% V1, 0% V3 for control and 9% V1, 91% V3 for PTU-treated animals).
isoforms across multiple mammalian species. In this study, we have determined that mouse cardiac V 1 myosin both hydrolyzes MgATP and moves actin filaments in the motility assay approximately two times faster than the V 3 isoform. However, in contrast to our earlier studies in the rabbit (11, 46) , where the V 3 myosin was found to generate twice the F avg of V 1 myosin, mouse V 1 and V 3 myosins are comparable in their average force-generating capacity, as previously observed in the rat (40, 41) . It is possible that rodent myosins may have shared similar evolutionary pressure to distinguish them from cardiac myosin obtained from larger mammals such as the rabbit. Can we begin to understand how the molecular mechanics and kinetics of the rodent cardiac myosins are altered to bring about the differences in V 1 and V 3 mechanical performance both within and across animal species?
Myosin molecular mechanics. At the molecular level, V actin is defined as V actin Ϸ d/t on , where d is the unitary displacement generated by the myosin power stroke and t on is the attachment time after the power stroke (1, 14) . Thus the faster V actin associated with the V 1 isoform can result from an increase in d, a decrease in t on, or a combination of the two. Single-molecule mechanical studies on cardiac myosin isoforms using the laser trap technique revealed that for both rat and rabbit V 1 myosin, d was unchanged whereas t on was decreased relative to V 3 myosin (26, 40) . Although we have not measured d for the mouse V 1 and V 3 myosins in the present study, we previously determined (44) d to be ϳ10 nm for mouse V 1 myosin, similar to the d for both rabbit V 1 and V 3 myosins (26) . Thus it appears that the kinetics (i.e., t on ) rather than the mechanics (i.e., d) of the myosin molecule accounts for the differences in V actin for the V 1 and V 3 myosins. In our earlier laser trap studies of the rabbit myosin (26), we were able to relate the decrease in t on for the V 1 compared with the V 3 myosin to a twofold increase in the rate of MgADP release from the myosin active site with no difference in MgATP binding. The difference in kinetics without a change in the molecular mechanics may be a universal theme across all muscle myosins, because differences in kinetics, specifically differences in the MgADP release rate (38) without differences in d have been determined at the molecular level to account for the range of V actin values that characterize skeletal, cardiac, and smooth muscle myosins (45) .
Although differences in V actin are uniformly reported for V 1 and V 3 myosin across all animal species studied to date, this is not the case for their force-generating capacity. Specifically, in this study the mouse cardiac V 1 and V 3 myosins exhibited similar F avg as previously reported for the rat (40, 41) . These results are in contrast to reports from our own laboratory for the rabbit (11, 46) , and if data from bovine V 1 and V 3 mixtures (7) are analyzed by our model, bovine V 3 also generates significantly more force than the V 1 isoform. In addition, VanBuren and coworkers recently observed greater F avg for human V 3 versus V 1 myosin (P. VanBuren, personal communication). Thus there appears to be a clear demarcation between rodents and larger mammals.
For the rabbit, we previously determined (46) that the higher F avg for V 3 versus V 1 myosin could be explained at the molecular level in the following manner: F avg Ϸ F ϫ f, where F is the myosin unitary force and f is the duty ratio, or the fraction of the entire crossbridge cycle time (t cycle ) that the myosin is attached to actin and generating force (i.e., f ϭ t on /t cycle ) (see Fig. 2 in Ref. 46 ). Given that F was similar for the rabbit V 1 and V 3 myosins in the laser trap, we concluded that the duty ratio must be higher for the rabbit V 3 myosin compared with the V 1 myosin (26) . Extending this logic to the mouse data, the lack of any difference between the V 1 and V 3 F avg estimates suggests that the duty ratio must be the same for the mouse V 1 and V 3 myosin, assuming that their unitary forces are similar. This in fact has been reported for the rat V 1 and V 3 myosins (40, 41) . Thus, if we assume that the total cycle times under isometric conditions are different by a factor of two, based on the mouse V 1 and V 3 myofibrillar ATPase measurements (with the caveat that these are unloaded estimates), then the rate-limiting step for detachment under isometric conditions might be coupled to the overall cycle time to maintain a constant duty ratio for the two isoforms (45) .
Given our laboratory's previous studies of cardiac myosin from different mammalian species, it is instructive to compare their V actin and F avg obtained from mixture assays. To facilitate this comparison, we have plotted the F avg for the various species relative to smooth muscle myosin (see Fig. 4 ) versus V actin for the individual cardiac isoforms. With smooth muscle myosin generating greater F avg than either of the V 1 and V 3 isoforms, a ratio greater than 1 is expected and the higher the ratio, the lower the F avg for the cardiac isoform. After plotting these data (see Fig. 4 ), it is obvious that there is a significant range in V actin for the cardiac myosins, with the mouse V 1 and V 3 myosins being faster than their respective rabbit and human isoforms. In contrast, it appears that all cardiac myosin isoforms generate the same F avg except for the rabbit VanBuren, personal communication), we assume that the bovine and human V 1 isoforms also generate significantly less F avg than their V 3 counterparts. Can we take advantage of this difference in both V actin and F avg across both myosin isoforms and species to help characterize the molecular structure and function relationships in these cardiac myosins?
Structural basis for differences in mechanical performance. Because of the high amino acid sequence identity (Ն93%) between the V 1 and V 3 isoforms for many mammals (i.e., hamster, mouse, rabbit, and human) as originally reported for the rat (21), comparison of the Fig. 3 . In vitro motility mixture assay for estimating the relative average force (Favg) for mouse cardiac V1 and V3 myosin. A: relationship between actin filament sliding velocity (Vactin) and % of mouse cardiac V1 and V3 within the myosin mixture that was applied to the motility surface. Solid line is the best fit to the mixtures model (11) and is linear, suggesting that the 2 myosins are of equal forcegenerating capacity. The fit resulted in a relative V1-to-V3 Favg ratio of 1.2 Ϯ 0.1. B: relationship between Vactin and % of mouse cardiac V1 and gizzard smooth muscle myosin within the myosin mixture. The fit resulted in a smooth muscle-to-V1 Favg ratio of 2.5 Ϯ 0.2. Note that the model fit is curvilinear and concave down, suggesting that smooth muscle myosin generates greater Favg than the mouse V1 myosin. C: relationship between Vactin and % of mouse cardiac V3 and gizzard smooth muscle myosin within the myosin mixture. The fit resulted in a smooth muscle-to-V3 Favg ratio of 3.5 Ϯ 0.5. As with the smooth muscle-V1 mixture, the model fit is curvilinear and concave down, suggesting that smooth muscle myosin generates greater Favg than the mouse V3 myosin. Fig. 4 . Favg for V1 and V3 cardiac compared with gizzard smooth muscle myosin from various species. All relative force measurements were obtained in the motility mixture assay and were determined previously in our laboratory in addition to the data presented here. The data are as follows: *rabbit ␣-and ␤-cardiac (11); # human ␤-cardiac (27) . To obtain the smooth-cardiac value it was assumed that the relative Favg for smooth-skeletal ϭ 2.1 (11) because the mixture was performed as a cardiac-skeletal mixture in this study. @ Mouse ␣-cardiac (44); $ mouse ␣-and ␤-cardiac from the present study (see Fig. 3 ). A relative Favg Ͼ1 suggests that the smooth muscle myosin generates greater force than the cardiac isoform. Note that the ␣-rabbit myosin generates the least force given the high smoothto-cardiac Favg ratio. In addition, there is a wide range of Vactin for the various cardiac isoforms. The linear regression and its 95% confidence limits were fit to the data excluding the ␣-rabbit myosin. For the myosins studied in our laboratory to date, all cardiac myosins generate similar Favg except for the ␣-rabbit myosin. V 1 and V 3 primary sequence should be a choice model system to identify structural domains important to these myosins' functional differences. With only 131 (i.e., 7%) nonidentical amino acids out of a total of 1,938 amino acids, it is then possible to map these differences on the skeletal S1 crystal structure (34) , which is presumably similar to the cardiac myosin structure (Fig. 5) . The majority of these amino acids are localized to five discrete regions of the molecule: 1) near the base of the catalytic domain and abutting the essential light chain, residues 32-36; 2) at the mouth and top of the nucleotide binding pocket, residues 210-214 (i.e., loop 1) and residues 349-351; 3) in surface loop 2 spanning the actin binding cleft, residues 619-641; 4) in the neck region or mechanical lever, residues 800-810; and 5) in the S2 segment, residues 1088-1094. Because these are the only regions of difference between the V 1 and V 3 isoforms, either one or several regions in combination must underlie the hydrolytic and mechanical differences observed. Therefore, it is not surprising that two of these regions of difference are ones that Spudich (39) proposed might tune the ATPase activity and V actin across myosin isoforms. Specifically, the structure of the surface loops that span the actin and nucleotide binding domains were thought to govern ATPase activity and V actin , respectively. However, this may not be universally applicable across all myosin isoforms (16, 29) , and in fact, there is no a priori reason to assume that differences in ATPase activity, V actin , and F avg for the V 1 and V 3 myosins will be linked to the same structural domain within the myosin molecule (45) . It will be instructive to make chimeric myosin in which different regions from the ␤-cardiac isoform are individually or in combination introduced into the ␣-cardiac myosin backbone. Similar studies have been performed in which either the cardiac nucleotide binding or actin binding loops have been engineered into heterologous myosin backbones such as smooth muscle or Dictyostelium myosins (23, 42) . Observed changes must be interpreted with caution given the heterologous nature of the myosin backbone.
Although there is significant sequence homology between the ␣-and ␤-cardiac isoforms within a mammalian species, there is even greater homology for similar isoforms across species (4, 29) . For example, when comparing all available mammalian ␣-cardiac myosin sequences through a multiple-sequence alignment (see MATERIALS AND METHODS), the sequences for the hamster, mouse, rat, rabbit, and human are 95% identical, with only 102 amino acids being substituted in one or more of the species. In fact, 86 of these residues are conservative substitutions, with the 16 remaining residues being nonconservative substitutions (see Tables 3 and  4) . We then took advantage of the fact that the mouse V 1 myosin has a faster V actin and generates a greater F avg than the rabbit V 1 (see Fig. 4 ) to help identify which of these 16 nonconservative substitutions may be responsible for the differences in mechanical performance between these two myosins. In fact, only eight nonconservative amino acid substitutions exist between the mouse and rabbit V 1 myosins (see Tables 3  and 4 ). Five of these differences are in the motor domain and neck region (residues 2, 210, 442, 452, and 801), whereas the remaining three are in the rod (residues 1092, 1637, and 1681).
A similar comparison was performed for the available mammalian ␤-cardiac myosin sequences, where the sequences for the hamster, mouse, rat, rabbit, pig, and human are 94% identical, with only 25 nonconservative substitutions (see Tables 5 and 6 ). Many of these 
See text for details of comparison. 
See text for details of comparison. http://ajpheart.physiology.org/ amino acids were previously identified through similar sequence comparisons in the rat, pig, and human (4, 29) . Once again, to help identify specific residues that might correlate with differences in myosin mechanical performance, we took advantage of our own data for the various V 3 myosins (Fig. 4) . Specifically, the mouse V 3 myosin has a twofold faster V actin than the rabbit isoform. Interestingly, these two isoforms differ by only four nonconservative amino acid substitutions (residues 424, 573, 1210, and 1368). In fact, only two of the four residues may have any functional impact (i.e., 424 and 573), given that residues 1210 and 1368 are identical for the mouse and human V 3 isoforms, where a twofold difference in V actin also exists, as with the rabbit. These amino acid substitutions, identified above, must account for the functional differences between V 1 and V 3 isoforms across species, and their localization within the molecule may confirm or potentially identify structural elements that are critical to myosin's functional performance. It is reasonable to assume that a few amino acid changes can have profound functional consequences. This fact is readily catalogued in the sarcomeric point mutations found in human familial hypertrophic cardiomyopathy (FHC) that have a profound effect on morbidity and mortality (33) . The first nonconserved residue at position 2 at the amino terminus for the V 1 rodent and rabbit myosins does not appear in any of the crystal structures, and so its relationship to the myosin structure is uncertain and thus it would be premature to speculate as to its importance. In contrast, residue 210 in these V 1 myosins exists within the surface loop that spans the nucleotide binding pocket. Both the length and flexibility of this loop have been proposed to modulate the rate at which nucleotide enters and leaves the nucleotide pocket (16, 42) and thus may impact on myosin's enzymatic and mechanical activities. Because these loops are of the same length in the rodent and rabbit V 1 , it is of interest that a proline at residue 210 in the rodents, which may confer reduced flexibility, is replaced by a valine in the rabbit. If the proline reduces loop flexibility, then MgADP may not exit the active site as rapidly. This might prolong the myosin attachment time relative to the total cycle time and thus increase the duty ratio in the rodent V 1 myosins relative to rabbit V 1 , accounting for the higher F avg for the mouse V 1 . Residues 424, 442, and 452 are in the upper 50-kDa segment of the myosin molecule as part of a long ␣-helix (residues 424, 442) and a linker strand (residue 452) that exits this helix. This helix borders the large cleft that separates the upper and lower 50-kDa segments. The extent to which this cleft opens and closes during the actomyosin cycle (9, 48) may play a crucial role in myosin functional performance. Thus having three residues that differ between the rodents and rabbit in this region of the myosin molecule as well as the nearby R453C mutation in FHC patients (52) further highlights the potential importance of this structural domain. The residue 573 substitution between the rodent and rabbit V 3 exists in a surface loop that may extend to an adjacent actin monomer that is not the primary actomyosin binding site and thus may serve as a secondary actin binding loop (4) . If so, it may then modulate the interaction kinetics between myosin and the actin filament. This could contribute to the twofold difference in V actin between the mouse and rabbit V 3 myosins. Residue 801 in the rodent and rabbit V 1 myosins resides within the essential light chain binding domain of the neck, i.e., myosin's mechanical lever (for review see Refs. 45, 51) . The importance of this region has also been emphasized by FHC point mutations that exist in this region (30) . Specifically, in vitro motility studies on these mutant myosins have demonstrated enhanced V actin . Thus the isoleucine for rodent V 1 being replaced by an alanine in the rabbit may account for the faster V actin in the rodents compared with the rabbit. Finally, the remaining amino acid differences exist within the rod (see Table  4 ). Although one might assume that differences in the coiled-coil rod segment should have little effect on the performance of the motor domain given their distance from the catalytic site, we are once again reminded that FHC mutations in this region can have profound effects (33) . For example, the L908V has been documented to have altered V actin compared with myosin from normal patients (6, 27) , with the alteration being related to changes in the myosin kinetics as determined in the laser trap assay (27) . It is possible that the stability of the coiled coil is critical to proper functioning of the two myosin heads. For example, Lauzon et al. (15) demonstrated that by stabilizing the rod near the head-neck junction by inserting a stable leucine zipper, one observed profound effects on the ability of these expressed myosin mutants to generate a power stroke, the assumption being that some unwinding or breathing of the coiled coil may be required for normal cooperative communication between the two heads (43) .
The extent to which one or any combination of these amino acids contributes to the differences in ATPase, V actin , and F avg between the rodent and rabbit V 1 and V 3 myosins is a matter of speculation. A functional consequence of any or all of these differences will only be determined by generating chimeric myosin in either the mouse or rabbit transgenic models, with the highest priorities being given to the four amino acids that are localized to the motor domain and neck (i.e., residues 210, 442, 452, and 801) of the ␣-cardiac backbone and the two amino acids (i.e., residues 424 and 573) in the ␤-cardiac backbone.
